Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease characterized by joint inflammation, structural damage, and associated skin manifestations of psoriasis. Despite the availability of several biologic and targeted therapies, many patients continue to experience persistent disease activity or treatment intolerance, highlighting the need for additional therapeutic options. Deucravacitinib (Sotyktu), an oral selective tyrosine kinase 2 (TYK2) inhibitor developed by Bristol Myers Squibb, has now received approval from the U.S. Food and Drug Administration for the treatment of adults with active psoriatic arthritis. This approval represents the first TYK2 inhibitor authorized for this indication and introduces a novel mechanism targeting intracellular cytokine signaling pathways involved in immune-mediated inflammation.
Duchenne muscular dystrophy (DMD) is a severe X-linked neuromuscular disorder characterized by progressive muscle degeneration caused by mutations in the dystrophin gene. Z-rostudirsen (DYNE-251) is an investigational exon-51–skipping therapy designed to restore the production of functional dystrophin by enabling targeted delivery of a phosphorodiamidate morpholino oligomer to muscle tissue. Dyne Therapeutics recently reported new cardiopulmonary and long-term clinical results from the Phase 1/2 DELIVER trial evaluating this therapy in individuals with DMD amenable to exon 51 skipping.
Neurofibromatosis type 1 (NF1) is a genetic disorder affecting approximately 1 in 3,000 individuals, characterized by the development of benign tumors, including plexiform neurofibromas (PN)—complex, infiltrative growths that often cause significant morbidity such as pain, disfigurement, functional impairment, and reduced quality of life. In adults, symptomatic, inoperable PN represent a particularly challenging subset, as surgical resection is frequently infeasible due to tumor encasement of vital structures, invasiveness, or vascularity, leaving limited therapeutic options.
